- Research article
- Open Access
- Open Peer Review
Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer
© Mezzasoma et al; licensee BioMed Central Ltd. 2010
- Received: 27 May 2010
- Accepted: 4 October 2010
- Published: 4 October 2010
at present, pathogenesis of bladder cancer (BC) has not been fully elucidated. Aim of this study is to investigate the role of human telomerase RNA (hTR), human telomerase reverse transcriptase (hTERT) and CDC28 protein kinase regulatory subunit 2 (CKS2) in bladder carcinogenesis and their possible clinical significance;
the transcript levels of hTR, hTERT and CKS2 were quantified by Real time reverse transcriptase chain reaction in exfoliated cells from bladder washings of 36 patients with BC and 58 controls. The statistical significance of differences between BC bearing patients and control groups, in the general as well as in the stratified analysis (superficial or invasive BC), was assessed by Student's t test. Non parametric Receiver Operating Characteristics analysis (ROC) was performed to ascertain the accuracy of study variables to discriminate between BC and controls. The clinical value of concomitant examination of hTR, hTERT and CKS2 was evaluated by logistic regression analysis;
a significant decrease in hTR and a significant increase in hTERT or CKS2 gene expression were found between BC bearing patients and controls, as well as in the subgroups analysis. The area under the curve (AUC) indicated an average discrimination power for the three genes, both in the general and subgroups analysis, when singularly considered. The ability to significantly discriminate between superficial and invasive BC was observed only for hTR transcript levels. A combined model including hTR and CKS2 was the best one in BC diagnosis;
our results, obtained from a sample set particularly rich of exfoliated cells, provide further molecular evidence on the involvement of hTR, hTERT and CKS2 gene expression in BC carcinogenesis. In particular, while hTERT and CKS2 gene expression seems to have a major involvement in the early stages of the disease, hTR gene expression, seems to be more involved in progression. In addition, our findings suggest that the studied genes have a clinical role in discriminating between BC and controls in the general as well as in the stratified analysis, when singularly considered. A combined model improved over the single marker BC diagnosis.
- Bladder Cancer
- Receiver Operating Characteristic
- Bladder Cancer Patient
- Invasive Bladder Cancer
- Superficial Bladder Cancer
Bladder cancer (BC) is one of the most common worldwide malignancies. In the Western world it is the fourth most common malignancy among men, following prostate, lung and colon cancers and represents the second most common cause of death among genitourinary tumors . BC consists of a heterogeneous group of tumors that display a broad clinical spectrum ranging from superficial and well differentiated lesions to invasive and poorly differentiated cancers, which represents a key problem in its management. While there is a wealth of molecular information on BC, it is still not possible to derive a clear model for the molecular pathogenesis of all these tumors . An enhanced understanding of the molecular biology of BC, could provide new insight into BC pathogenesis.
Telomerase is a specialized ribonucleoprotein complex including an RNA component, human telomerase RNA (hTR), and a catalytic protein, telomerase reverse transcriptase (hTERT), which stabilizes the telomeres of linear chromosomes [3, 4]. Although telomerase activity is present during human embryonic development, its expression and activity are repressed in most normal adult tissues. In contrast, most human tumours display high levels of telomerase [4–6]. Such an expression in cancer cells might be a necessary and essential step for tumor development and progression . On the other hand, other findings indicate that telomerase expression might not be an obligate requirement in some settings for initial tumor growth, but play an important role for long-term maintenance [7, 8]. Moreover, other observations suggest an additional role for telomerase during multistep oncogenesis . In particular, further developments indicate that telomere biology knowledge still remains incomplete, and implicate additional complexity in the relationship among telomeres, telomerase and cancer .
The subunit 2 of the cyclin kinase Cdc28/CDC2 (CKS2) is an essential component for cell cycle control, involved in cell cycle progression from G1 to S and from G2 to M . It has also been shown that CKS2 is essential for the first metaphase/anaphase transition of mammalian meiosis . Accumulating evidence shows an extensive expression of CKS2 in malignant tumors of different tissues, including meningioma  as well as prostate , cervical , gastric , colon and liver  carcinomas.
The role of telomerase or CKS2 in carcinogenesis, has made these molecules of growing interest in BC research. Regarding the former, studies have pointed out that telomerase activity as well as the mRNA expression levels of its subunits are associated with malignancy in many BC tumor histotypes [17–22]. In particular, the expression of hTERT and hTR mRNA, both in tissues  and in voided urine samples , seems to correlate positively with tumor stage and grade, even if these data have not, as yet, been confirmed . Hence, the biological relevance of telomerase remains to be fully elucidated and needs further investigation. Recently, CKS2 has been also studied in BC where it was significantly up-regulated, not only when BC was compared to normal bladder tissue, but also when invasive was compared to superficial BC . The difference in the CKS2 expression level between invasive BC and the normal bladder tissue was greater than between superficial BC and the normal bladder tissue, thus suggesting that CKS2 expression may influence BC progression via cell cycle advancement . At present, this is the only work to describe a possible role of CKS2 in this neoplasia.
The aim of this study was to investigate the biological role of hTR, hTERT and CKS2 in BC development and progression. Therefore, in the first part of the present study, we quantified the transcript levels of these molecules in samples particularly rich of exfoliated cells (bladder washings) from patients with or without BC.
Since we observed significant changes in the expression levels of the three considered genes between BC bearing patients and controls, we also decided to evaluate their possible role as molecular markers of BC diagnosis and progression.
The present project was developed at the Cell and Molecular Biology Laboratory of the University of Perugia together with the Urology Service of the University Hospital. The study protocol followed the guidelines of our local ethics committee and the investigation was conducted with the ethical requirements defined in the Helsinki Declaration. All patients gave their informed consent to participate in the study. The study included 94 consecutive patients undergoing flexible cystoscopy either for bladder cancer (BC) diagnosis or for other clinical indications. The subjects were classified into two age and sex matched groups. The first one included 36 patients (32 male, 4 female) with a histopathological diagnosis of BC. All these patients were at the first diagnosis of BC. Mean age ± SD of BC group was 68.8 ± 10.8 years (range 48 to 87). The second group (controls) included 58 patients (49 male, 9 female) with a mean age ± SD of 69.9 ± 10.6 years (range 41 to 86). Tumor stage was determined using TNM (Tumor lymph Nodes and Metastasis) and grading according to the World Health Organization (WHO 2004) guide lines. All tumors were classified as: 72.2% (26/36) superficial low grade [pTa (n = 24), pT1 (n = 2)], 27.8% (10/36) muscle invasive high grade [pT2-4 (n = 10)]. Among controls 24.1% (14/58) were patients with no history of malignancy (with hematuria/irritative symptoms) and 75.9% (44/58) were patients enrolled in a 2 years follow up from the time of BC diagnosis. At the time of sampling, all controls were BC free.
Collection of samples
60 ml of washing fluids were collected during flexible cystoscopy and immediately cooled on ice. Upon centrifugation at 4°C and 1200 rpm for 10 min, the sediments containing exfoliated cells were washed twice by suspension in ice-cold phosphate-buffered saline (PBS) and further centrifugation at 4°C and 1200 rpm for 10 min as well. Sediments thus obtained were snap frozen in TRIzol Reagent (Invitrogen, Milan, Italy), and stored at -70°C until subsequent use. We used bladder washes for detection of hTERT, hTR and CKS2 gene expression, because the number of exfoliated cells in these fluids has been shown to be higher than in voided urine . In addition, the sensitivity of bladder washes in detection of urothelial malignancy has been shown to be better than voided urine . Besides, cytology from bladder washing has been shown to be better than that from voided urine in the detection of bladder cancer [28, 29].
RNA isolation and cDNA synthesis
Total cellular RNA was isolated from the sediments using TRIzol Reagent (Invitrogen, Milan, Italy) according to the manufacturer's instructions. The quality and quantity of RNA was established spectrophotometrically by absorbance readings at 260 and 280 nm. Total RNA (1 μg) was reverse transcribed using the RevertAid™H Minus First Strand cDNA Synthesis Kit (Fermentas, Hanover, MD) and random primers System (Invitrogen, Milan, Italy). Following cDNA synthesis, the resulting mixture was heated at 95°C for 5 min before storage at -20°C.
Quantitative Real Time PCR analysis
Beacon Designer 4 software (Stratagene, La Jolla, CA) was used for the design of suitable combinations, either of TaqMan primers and probes or SYBR Green primers. The sequences of oligonucleotide primers and probes used for real time PCR were as follows: human telomerase RNA (hTR): 5'-cgccttccaccgttcattc-3' (sense, 400 nM), 5'-gctgacagagcccaactc-3' (antisense, 400 nM), 5'-FAM-agctgctggcccgttcgccc-TAMRA-3' (TaqMan Probe, 200 nM); human telomerase reverse transcriptase (hTERT): 5'-cgagagcagacaccagcag-3'(sense, 400 nM), 5'-cggacactcagccttcagc-3'(antisense, 400 nM); CDC28 protein kinase regulatory subunit 2 (CKS2): 5'-catgagccagaaccacatattc-3'(sense, 400 nM), 5'-cagctcatgcacaggtatgg-3'(antisense, 400 nM); β actin: 5'-cactcttccagccttccttcc-3'(sense, 600 nM), 5'-acagcactgtgttggcgtac-3'(antisense, 600 nM), 5'-Cy5-tgcggatgtccacgtcacacttca-BHQ2-3'(TaqMan Probe, 200 nM). Standards were prepared by classical PCR from cDNA obtained from LNCaP cell line (ATCC # CRL-1740) for the concerned target mRNAs. PCR products were purified from agarose gel using the Qiaquick DNA Fragment Purification kit (Qiagen, Milan, Italy), according to the manufacturer's instructions. Serial dilutions of each standard were subsequently prepared to obtain, following real time PCR amplification, the reference standard curve to extrapolate quantitative information for cDNA targets of unknown concentrations. Detection of specific mRNAs expression was carried out by either quantitative Real Time TaqMan or SYBR Green PCR analysis on a MX3005P Real-Time PCR System (Stratagene, La Jolla, CA). The amplification reactions were performed in quadruplicate for each sample. In our experiments, the calibration curves consisted of at least 6 points, and each concentration was run in triplicate. Only calibration curves with an R square (R2) value of 0.985-0.995 and efficiency between 90% and 100% were considered. Each PCR run consisted of the specific 6 point calibration curve, a no template control, and the specimen cDNAs.
As to CKS2, hTR, hTERT, and β actin (the housekeeping gene used for normalization), PCR reactions were performed in a total volume of 25 μl, containing 250 ng of cDNA for CKS2 and 500 ng for hTR and hTERT, 1× Brilliant QPCR master mix or Brilliant SYBR Green QPCR Master mix (Stratagene, La Jolla, CA), plus a concentration of specific primers and probes, as above described. The PCR conditions were: CKS2: 1 cycle at 95°C for 10 min, 45 cycles at 95°C for 15 s, 63°C for 1 min; hTR: 1 cycle at 95°C for 10 min, 45 cycles at 95°C for 30 s, 61°C for 1 min; hTERT: 1 cycle at 95°C for 10 min, 45 cycles at 95°C for 30 s, 64°C for 1 min, 72°C for 30 s; β actin: 1 cycle at 95°C for 10 min, 45 cycles at 95°C for 30 s, 64°C for 1 min, 72°C for 30 s.
The level of β actin expression was measured in all samples to normalize hTR, hTERT and CKS2 expression for sample-to-sample differences in total volume of bladder washings, numbers of exfoliated cells, RNA input, RNA quality, and reverse transcription efficiency.
The results concerning the groups of patients with or without BC were compared by χ2 test for categorical variables. The statistical significance of differences between BC patients and control groups was assessed by Student's t test. Differences were considered significant when P < 0.05. Most analyses were carried out using ln transformed variables to improve normality of distribution and data interpretability.
Nonparametric receiver operating characteristic analysis (ROC) was performed to assess the accuracy of study variables to discriminate between BC patients and controls [30, 31]. Logistic regression was used to assess the independent predictive ability of study variables. The individual probabilities of a positive outcome, based on the model coefficients, were used to calculate the AUCs after logistic regression.
Due to the asymmetry and large variability of the observed urinary concentrations, logistic regression was performed on ln transformed data. The logistic model was calculated in the presence of only 5% of missing data, thus not leading to biased results. A multinomial logistic model was fitted to study data for the following three categories: controls (reference), superficial bladder cancer (SBC) and invasive bladder cancer (IBC). Stata 10 SE was used to perform statistical analyses (Stata Corp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP).
Quantification of markers transcripts
Mean (± SE), 95% Confidence Interval (CI), median values for main study variables.
Mean (± SE)
Mean (± SE)
3.9 × 10-3 (±1.3 × 10-3)
1.3 × 10-3 -6.5 × 10-3
7.0 × 10-4
8.9 × 10-4 (±4.2 × 10-4)
3.5 × 10-5 -1.7 × 10-3
1.2 × 10-4
4.2 × 10-5 (±8.5 × 10-6)
2.4 × 10-5 -5.9 × 10-5
2.0 × 10-5
4.8 × 10-4 (±1.5 × 10-4)
1.7 × 10-4 -7.8 × 10-4
1.2 × 10-4
6.1 × 10-5 (±9.2 × 10-6)
4.2 × 10-5 -7.9 × 10-5
4.8 × 10-5
3.4 × 10-4 (±1.0 × 10-4)
1.3 × 10-4 -5.5 × 10-4
8.4 × 10-5
Mean (± SE), 95% Confidence Interval (CI), median values for main study variables.
Mean (± SE)
Mean (± SE)
Mean (± SE)
3.9 × 10-3
(±1.3 × 10-3)
1.3 × 10-3-6.5 × 10-3
7.03 × 10-4
1.2 × 10-3
(±5.6 × 10-4)
1.5 × 10-5-2.3 × 10-3
2.6 × 10-4
9.3 × 10-5
(±5.6 × 10-5)
-3.7 × 10-5-2.2 × 10-4
4.0 × 10-5
4.2 × 10-5
(±8.5 × 10-6)
2.4 × 10-5-5.9 × 10-5
2 × 10-5
4.7 × 10-4
(±1.7 × 10-4)
1.2 × 10-4-8.1 × 10-4
1.1 × 10-4
5.0 × 10-4
(±3.4 × 10-4)
-2.6 × 10-4-1.3 × 10-3
1.7 × 10-4
6.1 × 10-5
(±9.2 × 10-6)
4.2 × 10-5-7.9 × 10-5
4.8 × 10-5
3.8 × 10-4
(±1.4 × 10-4)
1.0 × 10-4-6.7 × 10-4
7.7 × 10-5
2.1 × 10-4
(±9.6 × 10-5)
-1.1 × 10-5-4.3 × 10-4
1.1 × 10-4
hTR, hTERT and CKS2 as molecular markers of bladder cancer
Logistic regression model for BC diagnosis.
In the attempt to evaluate the ability of each considered molecule in discriminating between SBC or IBC and controls, we performed ROC curves for each study variable. The AUCs values were 0.67 (95% CI: 0.56-0.77) for hTR, 0.75 (95% CI: 0.63-0.84) for hTERT and 0.65 (95% CI: 0.54-0.76) for CKS2. Such results pointed out an average discrimination power between controls and superficial forms for these tests, when singularly considered. The same analysis was performed for invasive forms. The AUCs values were 0.88 (95% CI: 0.78-0.95) for hTR, 0.78 (95% CI: 0.65-0.88) for hTERT and 0.72 (95% CI: 0.60-0.82) for CKS2. Finally, the ability to significantly discriminate between superficial and invasive BC was evaluated only for hTR transcript level (AUC: 0.78, 95% CI: 0.60-0.90, P = 0.0005). Therefore, all the three studied molecules appear to be suitable in discriminating superficial or invasive BC forms from controls. In addition, hTERT was the best one in discriminating BC superficial forms, while hTR was the best one in discriminating BC invasive forms.
Multinomial logistic model comparing controls (C, reference) with superficial (SBC) and invasive bladder cancer (IBC).
Bladder tumors show widely differing histopathology and clinical behavior. During the past 10 years, evidence has accrued on molecular pathways of bladder cancer (BC). However, molecular mechanisms of BC development and progression are not fully understood.
Our study characterizes the expression levels of three different genes associated with carcinogenesis: human telomerase RNA (hTR), human telomerase reverse transcriptase (hTERT) and CDC28 protein kinase regulatory subunit 2 (CKS2) in BC patients and controls. The evaluation was made in sediments from bladder washings, samples particularly rich of exfoliated tumor cells . The choice of using bladder washings is related to their usefulness and sensitivity in detecting urothelial malignancy, as it was previously shown [27, 28].
Our results point out a significant difference in the transcript levels of hTR, hTERT and CKS2 between BC and controls. In particular, when BC group was compared to controls, the former clearly showed a significant 4.4 fold decrease in hTR expression level. Such a result could be ascribed to specific regulation mechanisms at transcriptional level. In fact, transcriptional regulation is emerging as the main action controlling hTR gene expression . Multiple mechanisms regulate the hTR promoter in vivo  and a number of transcription factors have been implicated. In particular, in bladder cancer cells, a role for MDM2 in hTR promoter regulation, has been recently demonstrated . MDM2 associates with the hTR promoter and negatively regulates its activity , likely interfering with more than one transcriptional regulator in a dominant fashion .
The decrement in hTR expression, observed in our study, suggest its involvement in BC carcinogenesis. Until the present, studies in the literature described an increased expression of hTR in cancer patients with respect to healthy individuals [22, 23]. However, a peer comparison with such studies is quite difficult to interpret. In fact, to our knowledge, they refer to the evaluation of hTR mRNA levels in urine samples and the only study evaluating the expression of this molecule in washing fluids is not methodologically comparable .
Conversely, hTERT expression levels showed an 11.4 fold increment in BC group compared to controls, suggesting that its up regulation may have an important role in BC carcinogenesis. The observed hTERT over expression, could reflect the necessity in producing high levels of proteins required for its biological function. In fact, a significant association of telomerase activity with hTERT expression has been already previously shown [26, 34]. Such a higher expression in bladder washing fluids is in agreement with other previous findings [22–24, 26, 34–38].
With respect to CKS2, we observed a significant 5.6 fold up regulation in BC patients compared to controls, suggesting that aberrantly expressed CKS2 may contribute to BC initiation. Such a higher expression in bladder washing fluids is in agreement with the only report describing that CKS2 expression is strongly correlated with BC tumorigenesis .
Previous studies have shown that overexpression of cyclins D1 and E is associated with high levels of telomerase activity  and that CDK overexpression is required for telomerase activity in human and mouse cancer cells . Therefore, the parallel overexpression of hTERT and CKS2, observed in our study, could suggest a similar correlation also in BC and their involvement in a common regulatory pathway.
We then evaluated the mRNA expression level of hTR, hTERT and CKS2 in superficial and invasive BC compared to controls. With regard to hTR, a strong down regulation correlating with BC progression was observed, suggesting a possible role in the evolution of the disease.
Conversely, hTERT and CKS2 transcript levels were significantly up regulated in superficial forms, remaining almost unchanged in the invasive ones, thus suggesting a possible involvement of both of them in the early events during tumor development. There have been several attempts to correlate hTERT expression with BC staging and histological grading often with rather conflicting results  or with results that have not, as yet, been confirmed . The present study, provides further evidence supporting that hTERT mRNA expression is not related to tumor stage.
Regarding CKS2, the only report on this subject correlated CKS2 expression at tissue level, with tumor stage . The discrepancy between this study and ours may be due to the different analyzed specimen. In fact, the results emerging from tissue analysis, are not always paralleled by the same significance in other samples.
Although the field of tumor markers in BC is rapidly evolving no ideal marker currently exists. Among the innovative methods of detection, the employ of molecular markers is promising. Molecular assays usually produce more qualitative (categorical) results with higher sensitivity and reproducibility than the continuous data typically produced by biochemical assays [41, 42].
Since we observed significant changes in the expression levels of the three considered genes between BC and controls, we then evaluated their possible role as molecular markers of BC diagnosis and progression.
Calculating the Area Under the Receiver Operating Characteristic (ROC) curve (AUC), we assessed the discriminative ability of the transcript level concerning hTR, hTERT and CKS2 between BC and controls, when singularly considered (ROC areas ranging between 0.67-0.76). Subgroup analysis of the disease revealed that hTR, hTERT and CKS2 were able to discriminate between controls and superficial or invasive BC (AUCs ranging from 0.65 to 0.88).
Finally, our results suggest that a panel of markers, evaluated through the transcription of their genes, can be more useful than a single test for the diagnosis of BC. In particular, the combination of transcript levels of both hTR and CKS2 genes in the sediments of bladder washings, improves, over the single biomarker, BC diagnosis (AUC hTR/CKS2 0.87 vs AUCs ranging from 0.66 to 0.74). Hence, we agree with the general concept that for the diagnosis of heterogeneous diseases such as BC, the employment of a combined analysis of several markers seems to be the most promising approach .
With regard to subgroups analysis, the hTR/CKS2 combined model turned out to be useful in discriminating both superficial or invasive forms, compared to control. However, given the small number of invasive cancers, this may be regarded as an exploratory analysis.
Our results, obtained from a sample set particularly rich of exfoliated cells, provide further molecular evidence on the involvement of hTR, hTERT and CKS2 gene expression in bladder cancer (BC) carcinogenesis. In particular, while hTERT and CKS2 gene expression seems to have a major involvement in the early pathogenesis of the disease, hTR gene expression seems to be more associated with BC progression. Furthermore, the investigation of a possible clinical role of the three considered genes points out the ability to generally discriminate between control and BC, or superficial or invasive BC, when singularly considered. Finally, our results suggest that a panel of markers, evaluated through the transcription of their genes, can be more useful than a single test for diagnosis of BC. In particular, the combination of bladder washings transcript levels of both hTR and CKS2 genes improves, over the single biomarker, BC diagnosis. Further investigation will be necessary to confirm the role of hTR in BC progression.
Therefore, it could be of particular interest to extend the study to a larger population and to confirm these results in urine, to provide a useful non-invasive tool in detection and clinical evaluation of BC.
The authors thank the financial support from Fondazione CARIT and Roberta Frosini for the technical support.
- Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005, 66 (Supp 1): 4-34. 10.1016/j.urology.2005.07.062.View ArticlePubMedGoogle Scholar
- Knowles MA: Molecular pathogenesis of bladder cancer. Int J Clin Oncol. 2008, 13: 287-297. 10.1007/s10147-008-0812-0.View ArticlePubMedGoogle Scholar
- Blackburn EH: Telomeres and telomerase: their mechanisms of action and effects of altering their functions. FEBS Lett. 2005, 579: 859-862. 10.1016/j.febslet.2004.11.036.View ArticlePubMedGoogle Scholar
- Cairney CJ, Keth WN: Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie. 2008, 90: 13-23. 10.1016/j.biochi.2007.07.025.View ArticlePubMedGoogle Scholar
- Artandi SE, DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis. 2010, 31: 9-18. 10.1093/carcin/bgp268.View ArticlePubMedGoogle Scholar
- Hahn WC: Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003, 21: 2034-2043. 10.1200/JCO.2003.06.018.View ArticlePubMedGoogle Scholar
- Seger YR, García-Cao M, Piccinin S, Lo Cunsolo C, Doglioni C, Blasco MA, Hannon GJ, Maestro R: Transformation of normal human cells in the absence of telomerase activation. Cancer Cell. 2002, 2: 410-413. 10.1016/S1535-6108(02)00183-6.View ArticleGoogle Scholar
- Blackburn EH: Telomerase and cancer. Mol Cancer Res. 2005, 3 (Suppl 9): 477-482. 10.1158/1541-7786.MCR-05-0147.View ArticlePubMedGoogle Scholar
- Blasco M, Hahn WC: Evolving views of telomerase and cancer. Trends Cell Biol. 2003, 13: 289-294. 10.1016/S0962-8924(03)00085-0.View ArticlePubMedGoogle Scholar
- Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, Chaves SR, Spruck CH, Reed SI: Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol. 2008, 18: 5698-5709. 10.1128/MCB.01833-07.View ArticleGoogle Scholar
- Spruck CH, De Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ, Reed SI: Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis. Science. 2003, 300: 647-650. 10.1126/science.1084149.View ArticlePubMedGoogle Scholar
- Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol. 2009, 35: 1395-1407. 10.3892/ijo_00000457.View ArticlePubMedGoogle Scholar
- Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM, Wang F: Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 2008, 123: 543-551. 10.1002/ijc.23548.View ArticlePubMedPubMed CentralGoogle Scholar
- Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan SC, Chan LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK, Smith DI: Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer. 2006, 118: 2461-2469. 10.1002/ijc.21660.View ArticlePubMedGoogle Scholar
- Kang MA, Kim JT, Kim JH, Kim SY, Kim YH, Yeom YI, Lee Y, Lee HG: Upregulation of the cycline kinase subunit Cks2 increases cell proliferation rate in gastric cancer. J Cancer Res Clin Oncol. 2009, 135: 761-769. 10.1007/s00432-008-0510-3.View ArticlePubMedGoogle Scholar
- Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y: Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 2004, 24: 305-312.PubMedGoogle Scholar
- Bennett A: Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci. 2008, 21: 185-190.PubMedGoogle Scholar
- Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, Bercovich E, Ravaioli A, Amadori D, Calistri D: Relevance of urine telomerase in diagnosis of bladder cancer. JAMA. 2005, 294: 2052-2056. 10.1001/jama.294.16.2052.View ArticlePubMedGoogle Scholar
- Muller M: Telomerase: Its clinical relevance in the diagnosis of bladder cancer. Oncogene. 2002, 21: 650-655. 10.1038/sj.onc.1205071.View ArticlePubMedGoogle Scholar
- Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY: Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res. 1998, 4: 535-438.PubMedGoogle Scholar
- Bravaccini S, Sanchini MA, Granato AM, Gunelli R, Nanni O, Amadori D, Calistri D, Silvestrini R: Urine telomerase activity for the detection of bladder cancer in females. J Urol. 2007, 178: 57-61. 10.1016/j.juro.2007.03.025.View ArticlePubMedGoogle Scholar
- Takihana Y, Tsuchida T, Fukasawa M, Araki I, Tanabe N, Takeda M: Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Int J Urol. 2006, 13: 401-408. 10.1111/j.1442-2042.2006.01300.x.View ArticlePubMedGoogle Scholar
- Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, Miller K, Muller M: Quantitative evaluation of telomerase subunits in urine as biomarkers for non invasive detection of bladder cancer. Int J Cancer. 2005, 117: 274-280. 10.1002/ijc.21168.View ArticlePubMedGoogle Scholar
- Bowles L, Bialkowska-Hobrzanska H, Bukala B, Nott L, Razvi H: A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol. 2004, 11: 2438-2444.PubMedGoogle Scholar
- Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H, Nishiyama K, Takiguchi M, Nakagawa M, Seki N: Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep. 2006, 16: 521-531.PubMedGoogle Scholar
- Isurugi K, Suzuki Y, Tanji S, Fujioka T: Detection of the presence of catalytic subunit mRNA associated with telomerase gene in exfoliated urothelial cells from patients with bladder cancer. J Urol. 2002, 168: 1574-1577. 10.1016/S0022-5347(05)64523-5.View ArticlePubMedGoogle Scholar
- Maitra A, Rathi A, Gazdar AF, Sagalowsky A, Ashfaq R: Expression of the RNA component of human telomerase (hTR) in ThinPrep preparation from bladder washings. Cancer. 2001, 93: 73-79. 10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
- Bergman J, Reznichek RC, Rajfer J: Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int. 2008, 101: 26-29.PubMedGoogle Scholar
- Van der Poel HG, Van Balken MR, Schamhart DH, Peelen P, de Reijke T, Debruyne FM, Schalken JA, Witjes JA: Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology. 1998, 51: 44-50. 10.1016/S0090-4295(97)00496-2.View ArticlePubMedGoogle Scholar
- DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.View ArticlePubMedGoogle Scholar
- Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.View ArticlePubMedGoogle Scholar
- Zhao J, Bilsland A, Hoare SF, Keith WN: Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Lett. 2003, 536: 111-119. 10.1016/S0014-5793(03)00038-3.View ArticlePubMedGoogle Scholar
- Zhao J, Bilsland A, Jackson K, Keith WN: MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer. 2005, 5: 6-14. 10.1186/1471-2407-5-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M: Expression of Human Telomerase Subunits and Correlation with Telomerase Activity in Urothelial Cancer. Clin Cancer Res. 1998, 4: 1603-1608.PubMedGoogle Scholar
- De Kok JB, Ruers JM, Van Muijen GNP, VanBokhoven A, Willems HL, Swinkels DW: Real-Time quantification of human telomerase reverse transcriptase in tumors and healty tissue. Clin Chem. 2000, 46: 313-318.PubMedGoogle Scholar
- Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M: Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology. 2003, 62: 362-367. 10.1016/S0090-4295(03)00254-1.View ArticlePubMedGoogle Scholar
- Fukui T, Nonomura N, Tokizane T, Sato E, Ono Y, Harada Y, Nishimura K, Takahara S, Okuyama A: Clinical evaluation of human telomerase catalytic subunit in bladder washings from patients with bladder cancer. Mol Urol. 2001, 5: 19-23. 10.1089/109153601750124249.View ArticlePubMedGoogle Scholar
- De Kok JB, Van Balken MR, Roelofs RW, Van Aarssen YA, Swinkels DW, Klein Gunnewiek JM: Quantification of hTERT mRNA and telomerase activity in bladder washings of patients with recurrent urothelial cell carcinomas. Clin Chem. 2000, 46: 2003-2007.PubMedGoogle Scholar
- Landberg G, Nielsen NH, Nilsson P, Emdin SO, Cajander J, Roos G: Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res. 1997, 57: 549-554.PubMedGoogle Scholar
- Crowe DL, Nguyen DC: Rb and EF-1 regulates telomerase activity in human cancer cells. Biochim Biophys Acta. 2001, 1518: 1-6.View ArticlePubMedGoogle Scholar
- Shariat SF, Karam JA, Lerner SP: Molecular markers in bladder cancer. Curr Opin Urol. 2008, 18: 1-8. 10.1097/MOU.0b013e3282f1c5c1.View ArticlePubMedGoogle Scholar
- Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteom J. 2002, 1: 845-867. 10.1074/mcp.R200007-MCP200.View ArticleGoogle Scholar
- Birkhahn M, Mitra AP, Cote RJ: Molecular markers for bladder cancer: the road to multimarker approach. Expert Rev Anticancer Ther. 2007, 7: 1717-1727. 10.1586/14737220.127.116.117.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/10/17/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.